# Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer

> **NCT06548919** · — · RECRUITING · sponsor: **SciClone Pharmaceuticals** · enrollment: 450 (estimated)

## Conditions studied

- ESR1 Gene Mutation
- Advanced Breast Cancer

## Interventions

- **DRUG:** Endocrine therapy
- **DRUG:** Chemotherapy Prednisone

## Key facts

- **NCT ID:** NCT06548919
- **Lead sponsor:** SciClone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-08
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2024-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06548919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06548919, "Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06548919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*